These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34260404)

  • 1. A conserved epitope III on hepatitis C virus E2 protein has alternate conformations facilitating cell binding or virus neutralization.
    Deng L; Hernandez N; Zhong L; Holcomb DD; Yan H; Virata ML; Tarafdar S; Xu Y; He Y; Struble E; Alter HJ; Zhang P
    Proc Natl Acad Sci U S A; 2021 Jul; 118(28):. PubMed ID: 34260404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A neutralization epitope in the hepatitis C virus E2 glycoprotein interacts with host entry factor CD81.
    Zhao Z; Zhong L; Elrod E; Struble E; Ma L; Yan H; Harman C; Deng L; Virata-Theimer ML; Liu P; Alter H; Grakoui A; Zhang P
    PLoS One; 2014; 9(1):e84346. PubMed ID: 24400084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation and Characterization of Monoclonal Antibodies against a Cyclic Variant of Hepatitis C Virus E2 Epitope 412-422.
    Sandomenico A; Leonardi A; Berisio R; Sanguigno L; Focà G; Focà A; Ruggiero A; Doti N; Muscariello L; Barone D; Farina C; Owsianka A; Vitagliano L; Patel AH; Ruvo M
    J Virol; 2016 Jan; 90(7):3745-59. PubMed ID: 26819303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2.
    Vasiliauskaite I; Owsianka A; England P; Khan AG; Cole S; Bankwitz D; Foung SKH; Pietschmann T; Marcotrigiano J; Rey FA; Patel AH; Krey T
    mBio; 2017 May; 8(3):. PubMed ID: 28512091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors.
    Lavie M; Sarrazin S; Montserret R; Descamps V; Baumert TF; Duverlie G; Séron K; Penin F; Dubuisson J
    J Virol; 2014 Sep; 88(18):10584-97. PubMed ID: 24990994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discrete conformations of epitope II on the hepatitis C virus E2 protein for antibody-mediated neutralization and nonneutralization.
    Deng L; Ma L; Virata ML; Zhong L; Yan H; Zhao Z; Struble E; Feinstone S; Alter H; Zhang P
    Proc Natl Acad Sci U S A; 2014 Jul; 111(29):10690-5. PubMed ID: 25002515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes.
    Hadlock KG; Lanford RE; Perkins S; Rowe J; Yang Q; Levy S; Pileri P; Abrignani S; Foung SK
    J Virol; 2000 Nov; 74(22):10407-16. PubMed ID: 11044085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies.
    Meola A; Tarr AW; England P; Meredith LW; McClure CP; Foung SK; McKeating JA; Ball JK; Rey FA; Krey T
    J Virol; 2015 Feb; 89(4):2170-81. PubMed ID: 25473061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.
    Keck ZY; Li SH; Xia J; von Hahn T; Balfe P; McKeating JA; Witteveldt J; Patel AH; Alter H; Rice CM; Foung SK
    J Virol; 2009 Jun; 83(12):6149-60. PubMed ID: 19321602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33.
    Tarr AW; Owsianka AM; Timms JM; McClure CP; Brown RJ; Hickling TP; Pietschmann T; Bartenschlager R; Patel AH; Ball JK
    Hepatology; 2006 Mar; 43(3):592-601. PubMed ID: 16496330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HCV Glycoprotein Structure and Implications for B-Cell Vaccine Development.
    Ströh LJ; Krey T
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32947858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A view of the E2-CD81 interface at the binding site of a neutralizing antibody against hepatitis C virus.
    Harman C; Zhong L; Ma L; Liu P; Deng L; Zhao Z; Yan H; Struble E; Virata-Theimer ML; Zhang P
    J Virol; 2015 Jan; 89(1):492-501. PubMed ID: 25339761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibody.
    Li Y; Pierce BG; Wang Q; Keck ZY; Fuerst TR; Foung SK; Mariuzza RA
    J Biol Chem; 2015 Apr; 290(16):10117-25. PubMed ID: 25737449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Junctional and somatic hypermutation-induced CX
    Yi C; Xia J; He L; Ling Z; Wang X; Yan Y; Wang J; Zhao X; Fan W; Sun X; Zhang R; Ye S; Zhang R; Xu Y; Ma L; Zhang Y; Zhou H; Huang Z; Niu J; Long G; Lu J; Zhong J; Sun B
    Cell Mol Immunol; 2021 Mar; 18(3):675-685. PubMed ID: 32235917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody.
    Potter JA; Owsianka AM; Jeffery N; Matthews DJ; Keck ZY; Lau P; Foung SK; Taylor GL; Patel AH
    J Virol; 2012 Dec; 86(23):12923-32. PubMed ID: 22993159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein.
    Owsianka AM; Tarr AW; Keck ZY; Li TK; Witteveldt J; Adair R; Foung SKH; Ball JK; Patel AH
    J Gen Virol; 2008 Mar; 89(Pt 3):653-659. PubMed ID: 18272755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural evidence for a bifurcated mode of action in the antibody-mediated neutralization of hepatitis C virus.
    Deng L; Zhong L; Struble E; Duan H; Ma L; Harman C; Yan H; Virata ML; Zhao Z; Feinstone S; Alter H; Zhang P
    Proc Natl Acad Sci U S A; 2013 Apr; 110(18):7418-22. PubMed ID: 23589879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes.
    Gu J; Hardy J; Boo I; Vietheer P; McCaffrey K; Alhammad Y; Chopra A; Gaudieri S; Poumbourios P; Coulibaly F; Drummer HE
    J Virol; 2018 May; 92(9):. PubMed ID: 29467319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probing the antigenicity of hepatitis C virus envelope glycoprotein complex by high-throughput mutagenesis.
    Gopal R; Jackson K; Tzarum N; Kong L; Ettenger A; Guest J; Pfaff JM; Barnes T; Honda A; Giang E; Davidson E; Wilson IA; Doranz BJ; Law M
    PLoS Pathog; 2017 Dec; 13(12):e1006735. PubMed ID: 29253863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions.
    Keck ZY; Op De Beeck A; Hadlock KG; Xia J; Li TK; Dubuisson J; Foung SK
    J Virol; 2004 Sep; 78(17):9224-32. PubMed ID: 15308717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.